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S u m m a r y  
 
I n t r o d u c t i o n .  The aim of this study is to analyze 
the characteristics of patients in whom leg amputation was 
performed due to critical limb ischemia (CLI). 
M a t e r i a l  a n d  m e t h o d s .  Retrospective analysis 
of the characteristics of patients who underwent leg 
amputation between 2012 and 2014 in our center. 
R e s u l t s .  Between 2012 and 2014, 39 amputations of 
37 limbs were performed on 32 patients treated due to CLI. 
Amputations amounted to 39/1282 (3.2%) of all vascular 
procedures performed on the lower limbs. They concerned, 
respectively: forefoot – 49%, calf – 15%, and thigh – 36%. In 
85% of patients, the amputations were preceded by vascular 
procedures. The median length of time between the first 
revascularization procedure and amputation amounted to 99 
± 8-1088 days. Patients who underwent primary amputation 
(n = 6, 15%) compared to the individuals with secondary 
amputation were treated less frequently with aspirin (67% vs. 
97%; p = 0.01) and statins (50% vs. 94%, p = 0.002). Patients 
who underwent amputation at thigh level compared with 
subjects with forefoot amputation were hospitalized for a 
significantly longer period of time, diagnosed more often 
with chronic heart failure (CHF) and chronic kidney disease 
(CKD), and were more often tobacco smokers.  
C o n c l u s i o n s .  The main factors determining the 
need for amputation, its level and time between the first 
revascularization procedure and leg amputation were: the 
number of preceding procedures and stent implantations, 
comorbidity of CHF and CKD, smoking habit, inadequate 
pharmacotherapy (probably due to delayed diagnosis), 
severity of angiographic lesions, and higher MPV and INR 
values. 
 
S t r e s z c z e n i e  
 
W s t ę p .  Celem niniejszej pracy było przedstawienie 
charakterystyki pacjentów poddanych amputacji kończyn 
dolnych z powodu krytycznego niedokrwienia (CLI)  
w jednym ośrodku angiologicznym.  
P a c j e n c i  i  m e t o d y .  W latach 2012-2014  
w klinice wykonano 39 amputacji kończyn dolnych, na 37 
kończynach, u 32 pacjentów leczonych z powodu CLI.  
W y n i k i .  Amputacje kończyn dolnych stanowiły 
39/1282 (3%) wszystkich procedur naczyniowych na 
tętnicach kończyn dolnych. 49% amputacji dotyczyło 
przodostopia, 15% podudzia oraz 36% uda; 85% amputacji 
przeprowadzono na kończynach, które wcześniej były 
rewaskularyzowane. Średni czas między pierwszym zabie-
giem naczyniowym a amputacją kończyny wynosił 99 ±  
8-1088 dni. Pacjenci poddani pierwotnej amputacji rzadziej 
przyjmowali aspirynę (67% vs. 94%; p=0,01) oraz statyny 
(50% vs. 94%, p=0,002). Pacjenci z amputacją na udzie,  
w porównaniu z osobami z amputowanym przodostopiem, 
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byli w związku z zabiegiem dłużej hospitalizowani, częściej 
mieli rozpoznaną przewlekłą niewydolność serca (PNS)  
i nerek (PNN), częściej palili i rzadziej przebyli udar mózgu. 
Nie stwierdzono różnic częstości występowania cukrzycy  
i dyslipidemii oraz nasilenia zmian angiograficznych. Zakres 
amputacji korelował m.in z wcześniejszą diagnozą PNS 
i PNN, przebyciem udaru mózgu, wartością MPV, INR  
i kreatyniny. Czas między wykonanym zabiegiem naczynio-
wym a amputacją korelował znamiennie m.in. z: liczbą 
wykonanych zabiegów i stentów implantowanych podczas 
pierwszego zabiegu.  
W n i o s k i .  15% pacjentów z CLI trafiało do szpitala  
w stanie uniemożliwiającym podjęcie zabiegu rewaskula-
ryzacyjnego. Czynnikami determinującymi konieczność 
amputacji i jej zakres były: liczba wcześniejszych zabiegów  
i implantacji stentów, współistniejące PNS i PNN, palenie 
tytoniu, nieadekwatna farmakoterapia (opóźnienie diagno-
zy?), nasilenia zmian angiograficznych oraz wyższe wartości 
MPV i INR; nie wpływały na nią natomiast cukrzyca  
i dyslipidemia.  
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There is a great deal of evidence indicating that 
primary amputation is still one of the main procedures 
in acute as well as chronic limb ischemia treatment. In 
some countries, an amputation is the first choice of 
treatment in as many as 67% of patients with critical 
limb ischemia (CLI). In this group, 31.8 - 50% of 
patients undergo leg amputation without an earlier 
diagnosis [1]; arteriography is performed in 16% of 
patients, the ankle-brachial index (ABI) is measured in 
35% of patients, and only 26% consult a cardiologist 
and 21% - a vascular surgeon. Perioperative mortality 
rate related to limb amputation in the US ranges from  
4 to 30% in different institutions and the 12-month rate 
increases to 45%. These data show that peripheral 
artery disease (PAD) is still not diagnosed and 
managed correctly.   
According to Yost, approximately 65-75 thousand 
major amputations (above and below the knee) are 
performed annually due to CLI [2]. The annual direct 
cost of CLI treatment in the US exceeds $25 billion. 
Furthermore, the 5-year mortality rate of 70% for 
patients with CLI means that the number of deaths 
attributed to CLI is higher than the  total of deaths due 
to coronary artery disease (CAD), breast cancer and 
colorectal cancer over the same period. To the 
previously mentioned health and social consequences 
of lower limb amputation, the costs of prosthetic, 
orthopedic, rehabilitation and work absence should 
also be added. However, it seems that proper 
prevention and management of PAD might reduce the 
impact of these health and social consequences, limit 
the use of public health system resources, and improve 
the quality of life not only for the patients, but also for 
their families. All the above-mentioned data show that 
the need for leg amputation in patients  with  PAD  is 
 
 
a critical issue. Therefore, any investigation which 
might help to identify the risk factors for leg 
amputation, both primary and secondary, is justified 
and necessary. These types of investigation could help 
to introduce a strategy for leg amputation prevention 
based on risk factor stratification. As these risk factors 
characterize patients with primary and secondary leg 
amputation, we conducted our study to identify them in 
our own material.    
 
MATERIAL AND METHODS 
 
Clinical data related to 41 lower limb amputations 
performed between 2012 and 2014 in our clinic were 
retrospectively analyzed. 
We were given a permission to conduct the analysis 
by the local Bioethical Commission on 02.18.2014 in 
accordance with an annex from 04.21.2015. The study 
was conducted in accordance with the Revised 
Declaration of Helsinki.  
Statistical analysis was performed with 
STATISTICA software for Windows 10.0 (StatSoft, 
Inc. 2011, STATISTICA, data analysis software 
system, version 10). The results are expressed as mean 
± standard deviation. Non-parametric tests were used 
to compare the values between the groups due to the 
inability to refute the hypothesis of the absence of a 
normal distribution (Shapiro-Wilk test): the Mann-
Whitney U test and the Fisher’s exact test. The 
Spearman’s rank correlations were checked. The 
variables determining the time duration between the 
first revascularization procedure and the amputation 
were analyzed using progressive stepwise regression. 
The statistical significance level was set at a P-value  
< 0.05. 





During 2012 and 2014, 41 lower limb amputations 
were performed in our clinic. They involved 39 limbs 
of 32 patients with CLI. During this time, 8285 patients 
were treated in our clinic, of whom 1437 (17.3%) were 
treated with any intervention. Of these interventions, 
1010/1437 (70.3%) were endovascular, of which 
673/1010 (66.7%) concerned lower extremities. The 
remaining operations included 240/1437 (16.7%) 
surgical procedures, among which 85/240 (35.4%) 
concerned lower limb vascular procedures, and 
187/1437 (13%) hybrid procedures, which combined 
endovascular and surgical methods on leg vessels. 
Lower limb amputations amounted to 41/240 (17%) of 
all surgical procedures and 41/945 (4.3%) of all 
procedures concerning the vessels of the lower limbs. 
Among the amputations analyzed, 21/41 (51%) 
concerned the forefoot, 6/41 (15%) the calf and 14/41 
(34%) the thigh. The reasons for amputation were as 
follows: in 18 cases (44%), extensive necrosis or its 
progression, in 21 cases (51%) infected necrosis, and 
in two (5%) cases the lack of wound healing after less 
extensive amputation. None of the patients experienced 
a cardiovascular event during hospitalization or in the 
30 days after being discharged home.  
One patient had three successive amputations of the 
same leg during the same hospitalization. In the 
subsequent analysis, this patient was counted as an 
individual with thigh level amputation. This gives 39 
amputations overall, as shown in Table 1. Thus, 39 leg 
amputation procedures during separate hospitalizations 
are included in the analysis presented in Table 1. In six 
(15%) patients, leg amputation was conducted as a 
primary procedure (on a limb that had not previously 
been revascularized), and in the remaining 33 (85%) 
amputations were performed on a previously 
revascularized limb due to CLI (Rutherford class 4-6), 
where revascularizations were both endovascular 
(100%) and surgical (13/33; 39%). Each of the 39 
amputation procedures analyzed had been treated with 
vascular procedures between one and five times, which 
resulted in a total of 54 interventions. The average time 
between the first procedure on the limb and amputation 
amounted to 220.4 ± 272.7 days (median 99 days, 
range: 8-1088 days).  
Patients who underwent primary amputation were 
not significantly different from the patients who had 
been treated with vascular procedures before the 
amputation (secondary amputation) when it came to 
the following: length of hospitalization due to 
amputation, the level of the amputation, a prior 
amputation on other lower limb, the existence of 
infected necrosis or diabetes mellitus prevalence 
(Table 1). There had also not been any significant 
differences in the concentration of glucose, low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides or creatinine in the 
blood (Table 1). However, in the group of patients with 
a primary amputation, left lower limb amputation was 
significantly more frequent and the patients were 
slightly younger. Moreover, they took aspirin, 
clopidogrel and statins less often than individuals with 
a secondary leg amputation. 
Next, we analyzed factors affecting the level of the 
leg amputation. The patients who had a thigh-level 
amputation (n = 14/39, 36%) were hospitalized 
significantly longer (15.1 ± 6.5 days vs. 7.2 ± 5.2 days) 
compared to the patients who underwent a forefoot-
level amputation (n = 20/39, 51%) (Table 2). The 
group of patients with a thigh-level amputation was 
significantly older, more often diagnosed with chronic 
heart failure (CHF) and chronic kidney disease (CKD). 
Smoking was not significantly less prevalent among 
thigh-level amputees (43% vs 67%) and this group was 
more likely to have a history of stroke (36% vs 5%) 
(Table 2). They also had higher mean platelet volume 
(MPV), greater platelet distribution width (PDW) and a 
higher creatinine level. However, diabetes mellitus, 
blood glucose, LDL and HDL cholesterol, and 
triglycerides were similar in both groups. There was 
also no difference in initial angiographic lesion 
severity at the aortoiliac femoropopliteal level below 
the knee, or on the foot. Patients with a thigh-level 
amputation had had significantly more stents implanted 
before the amputation, the full length of these stents 
being significantly longer than in other patients. 
Following univariate analysis (Spearman’s rank 
correlation), the level of leg amputation (forefoot, calf, 
or thigh) correlated significantly with: length of 
hospitalization after amputation (R = 0.56; p = 0.0002); 
previous diagnosis of CHF (R = 0.34; p = 0.032); 
history of stroke (R = 0.36; p = 0.023); MPV value (R 
= 0.45; p = 0.0044); international normalized value 
(INR) value (R = 0.38; p = 0.019); history of chronic 
obstructive lung disease (COLD) (R = 0.46; p = 
0.0033); and creatinine level (R = 0.33; p = 0.040).  
However, the time between the first vascular 
procedure and amputation of this leg was closely 
related to the number of vascular procedures before the 
amputation (R = 0.64; p = 0.0001), hemoglobin value 
(R = -0.37; p = 0.035), leucocyte blood count (R = -
0.35; p = 0.047), and the number of stents implanted 
during the first procedure (R = 0.36; p = 0.044). The 
type of vascular procedure (surgical, intravascular, and 
hybrid) that had been performed before the amputation 
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had no statistically significant influence on the time 
between the first vascular procedure and amputation. 
The multivariate analysis based on stepwise 
progressive regression resulted in an equation 
explaining 99% of the inter-procedure variations in 
duration of the leg-saving period. This analysis showed 
this parameter as being determined by a number of 
factors (Table 3). 
 
Table 1. Comparison of clinical data of patients with primary 
amputation with patients who have had at least one 
revascularization procedure prior to the amputation 
(the analysis concerns 39 amputated legs 
Tabela 1. Porównanie danych klinicznych pacjentów  
z pierwotną amputacją z chorymi, którzy przed 
amputacją kończyny mieli na niej wykonany 
przynajmniej jeden zabieg rewaskularyzacyjny 











(n = 33; 85%) 
p 
Days hospitalized 10.5 ± 5.2 10.2 ± 6.7 0.90 
Amputation of the left limb 
(n, %) 6 (100%) 19 (58%) 0.047 
Range (forefoot/calf/thigh) (n, 
%) 
3 (50%)/ 1 
(17%) 
2 (33%) 




History of second leg 
amputation (n, %) 1 (17%) 8 (24%) 0.69 
Infection as a cause of 
amputation (n, %) 4 (67%) 17 (52%) 0.75 
Age (years) 59.7 ± 11.0 67.8 ± 9.4 0.065 
Male sex (n, %) 6 (100%) 23 (70%) 0.11 
CAD (n, %) 4 (67%) 14 (42%) 0.29 
CABG history (n, %) 0 (0%) 6 (18%) 0.27 
PCI history (n, %) 1 (17%) 4 (12%) 0.77 
CHF (n, %) 2 (33%) 11 (33%) 1.0 
Atrial fibrillation (n, %) 2 (33%) 9 (27%) 0.77 
Stroke history (n, %) 1 (16%) 5 (15%) 0.97 
Carotid artery stenosis  
(n, %) 0% 5 (15%) 0.32 
COLD (n, %) 1 (17%) 3 (9%) 0.59 
Tobacco smoking (n, %) 4 (67%) 18 (56%) 0.59 
Arterial hypertension (n, %) 5 (83%) 30 (91%) 0.59 
Diabetes mellitus (n, %) 4 (67%) 18 (55%) 0.93 
Anemia (n, %) 5 (83%) 21 (64%) 0.36 
CKD (n, %) 3 (50%) 9 (27%) 0.28 
Dyslipidemia (n, %) 2 (33%) 22 (67%) 0.24 
LDL cholesterol (mg/dl) 98.8 ± 23.9 112.0 ± 38.9 0.48 
Triglycerides (mg/dl) 118.2 ± 29.6 122.4 ± 46.0 0.85 
Glucose (mg/dl) 177.3 ± 51.6 160.1 ± 71.9 0.58 
Erythrocytes (T/l) 3.6 ± 0.6 3.9 ± 0.5 0.14 
Hemoglobin (g/dl) 10.8 ± 1.7 11.4 ± 1.9 0.49 
Hematocrit (%) 33.0 ± 4.4 34.5 ± 5.3 0.53 
MCV (fl) 92.5 ± 6.1 88.4 ± 4.9 0.075 
MCH (pg) 30.2 ± 1.5 29.0 ± 1.7 0.13 
Leukocytes (G/l) 12.4 ± 6.0 13.9 ± 6.3 0.57 
CRP (mg/dl) 110.9 ± 56.6 78.2 ± 71.5 0.34 
Platelets (G/l) 410.5 ± 226.6 346.3 ± 124.9 0.32 
MPV (fl) 8.6 ± 1.2 13.3 ± 17.9 0.53 
INR 1.15 ± 0.098 1.14 ± 0.2 0.89 
aPTT (s) 34.1 ± 6.9 32.0 ± 5.7 0.41 
Creatinine (mg/dl) 1.99 ± 1.11 1.37 ± 0.80 0.11 
GFR (ml/min) 55.2 ± 37.3 76.5 ± 29.5 0.16 
Aspirin therapy (n, %) 4 (66%) 32 (97%) 0.01 
Clopidogrel therapy (n, %) 1 (17%) 23 (70%) 0.013 
Oral anticoagulant therapy 
(n, %) 2 (33%) 20 (61%) 0.23 
Statin therapy (n, %) 3 (50%) 31 (94%) 0.002 
ACEI therapy (n, %) 5 (83%) 26 (79%) 0.81 
Calcium channel blocker 
therapy (n, %) 0 7 (21%) 0.22 
Beta-blocker therapy (n, %) 4 (69%) 23 (70%) 0.89 
Abbreviations: CAD = coronary artery disease; CABG = coronary 
artery bypass graft; PCI = percutaneous coronary intervention; CHF 
= coronary heart failure; COLD = chronic obstructive lung disease; 
CKD = chronic kidney disease; LDL = low-density lipoprotein; 
MCV = mean corpuscular volume; MCH = mean corpuscular 
hemoglobin; CRP = C-reactive protein; MPV = mean platelet 
volume; INR = international normalized ratio; aPTT = activated 
partial thromboplastin time; GFR = glomerular filtration rate; ACEI 
= angiotensin converting enzyme inhibitor 
 
Table 2. Comparison of the characteristics of patients with 
an amputation performed at the thigh level with 
patients who underwent amputation at the forefoot 
level (analysis per procedure) 
Tabela 2. Porównanie charakterystyki pacjentów z amputa-
cją wykonaną na udzie w porównaniu z chorymi,  






thigh amputation  















Days hospitalized due to 
amputation 
Dni hospitalizacji związanej 
z amputacją 
15.14 ± 6.5 7.21 ± 5.2 0.0005 
Length of time between 
procedure and amputation 
(days) 
czas między zabiegiem a 
amputacją (dni) 
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Left limb amputation (n, %) 
Amputacja lewej kończyny (n, 
%) 
10 (71%) 13 (68%) 0.86 
History of second leg 
amputation (n, %) 
Amputacja drugiej kończyny 
dolnej w wywiadzie (n, %) 
4 (29%) 3 (16%) 0.27 
Age (years) 
Wiek (lata) 
69.3 ± 7.2 62.2 ± 9.5 0.026 
Male sex (n, %) 
płeć męska (n, %) 
11 (79%) 14 (74%) 0.76 
CAD  (n, %) 
Choroba niedokrwienna serca 
(n, %) 
9 (64%) 7 (37%) 0.13 
CABG history (n, %) 
CABG w wywiadzie (n, %) 
1 (7%) 4 (21%) 0.29 
PCI history (n, %) 
PCI wieńcowe w wywiadzie 
(n, %) 
2 (14%) 1 (5%) 0.39 
CHF (n, %) 
Przewlekła niewydolność serca 
(n, %) 
7 (50%) 3 (16%) 0.035 
*Atrial fibrillation (n, %) 
Migotanie przedsionków  
(n, %) 
6 (43%) 5 (26%) 0.33 
Stroke history (n, %) 
Przebyty udar (n, %) 
5 (36%) 1 (5%) 0.029 
Carotid artery stenosis (n, %) 
Zwężenie tętnicy szyjnej (n, 
%) 
2 (14%) 2 (10%) 0.75 
COLD (n, %) 
POCHP (n, %) 
1 (7%) 2 (10%) 0.75 
Tobacco smoking (n, %) 
Palenie (n, %) 
6 (43%) 14 (74%) 0.077 
Arterial hypertension (n, %) 
Nadciśnienie tętnicze (n, %) 
13 (93%) 17 (89%) 0.75 
Diabetes mellitus (n, %) 
Cukrzyca (n, %) 
8 (57%) 11 (58%) 0.86 
Anemia (n, %) 
Niedokrwistość (n, %) 
12 (86%) 11 (58%) 0.091 
CKD (n, %) 
Niewydolność nerek (n, %) 
8 (57%) 2 (10%) 0.003 
Dyslipidemia (n, %) 
Dyslipidemia (n, %) 
10 (71%) 10 (48%) 0.83 
LDL cholesterol (mg/dl) 
Cholesterol LDL (mg/dl) 


















3.8 ± 0.6 4.0 ± 0.5 0.34 
Hemoglobin (g/dl) 
Hemoglobina (g/dl) 
10.9 ± 2.0 11.7 ± 1.9 0.25 
Hematocrit (%) 
Hematokryt (%) 
33.4 ± 5.4 35.2 ± 5.4 0.35 
MCV (fl) 
MCV (fl) 
89.2 ± 7.3 88.9 ± 3.7 0.92 
MCH (pg) 
MCH (pg) 
29.0 ± 2.1 29.3 ± 1.5 0.62 




88.2 ± 59.7 56.9 ± 59.9 0.19 
Platelet count (G/l) 
Płytki krwi (G/l) 






19.6 ± 26.3 8.4 ± 0.9 0.08 
INR 
INR 
1.2 ± 0.2 1.1 ± 0.2 0.32 
aPTT (s) 
aPTT (s) 
34.5 ± 7.3 31.2 ± 4.2 0.11 
Creatinine (mg/dl) 
Kreatynina (mg/dl) 
2.0 ± 1.2 1.13 ± 0.2 0.005 
GFR (ml/min) 
GFR (ml/min) 
62.9 ± 36.3 82.0 ± 24.7 0.086 
Aspirin therapy (n, %) 
Leczenie aspiryną (n, %) 
14 (100%) 16 (84%) 0.13 
Clopidogrel therapy (n, %) 
Leczenie klopidogrelem  
(n, %) 
11 (79%) 9 (47%) 0.07 
Oral anticoagulant therapy (n, 
%) 
Doustny antykoagulant (n, %) 
9 (64%) 8 (42%) 0.22 
Statin therapy (n, %) 
Leczenie statyną (n, %) 
12 (85%) 16 (84%) 0.91 
ACEI therapy (n, %) 
Leczenie ACEI (n, %) 
10 (71%) 16 (84%) 0.39 
Calcium channel blocker 
therapy (n, %) 
Leczenie blokerem kanałów 
wapniowych (n, %) 
3 (21%) 4 (21%) 0.98 
Beta-blocker therapy (n, %) 
Leczenie beta-blokerem (n, %) 
12 (86%) 11 (58%) 0.091 
Endovascular procedure 
history (n, %) 
Wcześniejsze zabiegi 
wewnątrznaczyniowe (n, %) 
12 (86%) 15 (79%) 0.63 
Severity of changes at 
aortoiliac level according to 
TASC II (0/A/B/C/D) 
Zaawansowanie zmian  
w odcinku aortalno- 
biodrowym wg TASC II 
(0/A/B/C/D) 
7(50%) / 1(7%) / 








Severity of changes at 
femoropopliteal level 
according to TASC II 
(0/A/B/C/D) 
Zaawansowanie zmian w 
odcinku udowo- 
podkolanowym wg TASC II 
(0/A/B/C/D) 
3(22%) / 4(38%) /  








Number of permeable arteries 
in lower leg 
Liczba drożnych tętnic goleni 
2.2 ± 1.0 1.9 ± 1.0 0.49 
Number of permeable arteries 
in foot 
Liczba drożnych tętnic stopy  
1.3 ± 0.7 1.1 ± 0.9 0.58 
Level of the first 
revascularization (0 / aortoiliac 
/ femoropopliteal / below the 
knee / at least two segments) 
Poziom pierwszego zabiegu 
(0/aortalno-biodrowy/ udowo-
podkolanowy/ poniżej kolana, 
przynajmniej 2 segmenty) 
2(14%) / 3(22%) / 
2(14%) / 2(14%) / 
5(36%) 
4(19%) / 





Occlusion of treated artery 
(n, %) 
7 (50%) 12 (57%) 0.13 
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Niedrożność tętnicy poddanej 
zabiegowi (n, %) 
The number of stents 




wcześniejszego zabiegu (n) 
1.0 ± 1.0 1.3 ± 1.4 0.59 
Total length of the stents (mm) 
Suma długości stentów (mm) 
87.6 ± 46.3 110.5 ± 7.0 0.19 
Implantation of DES (n, %) 
Implantacja DES do tętnicy  
(n, %) 
8 (57%) 8 (39%) 0.71 
Use of DEB (n, %) 
Zastosowanie DEB (n, %) 
12 (86%) 15 (71%) 0.47 
Implantation of a stent into the 
popliteal artery during previous 
surgery (n, %) 
Implantacja stentu do tętnicy 
podkolanowej podczas 
wcześniejszego zabiegu (n, %) 
3 (21%) 4 (19%) 1.00 
TLR before amputation (n, %) 
Liczba zabiegów naprawczych 
(TLR) przed amputacją (n, %) 
10 (71%) 12 (57%) 0.31 
Abbreviations: CAD = coronary artery disease; CABG = coronary 
artery bypass graft; PCI = percutaneous coronary intervention; CHF 
= coronary heart failure; COLD = chronic obstructive lung disease; 
CKD = chronic kidney disease; LDL = low-density lipoprotein; 
MCV = mean corpuscular volume; MCH = mean corpuscular 
hemoglobin; CRP = C-reactive protein; MPV = mean platelet 
volume; INR = international normalized ratio; aPTT = activated 
partial thromboplastin time; GFR = glomerular filtration rate; ACEI 
= angiotensin converting enzyme inhibitor; DES = drug eluting stent; 
DEB = drug eluting balloon; TLR = target lesion revascularization 
 
Table 3. Results of the multivariate analysis based on 
progressive stepwise regression for the length of 
time between the first revascularization 
procedure and a secondary amputation in one 
leg. R = 0.99; R2 = 0.99; corrected R2 = 0.99; F 
(32.1) = 78292; p < 0.0028; estimated standard 
error = 0.99 
Tabela 3. Wyniki krokowo-postępującej regresji wielokrotnej 
dla czasu trwania okresu między pierwszym 
zabiegiem rewaskularyzacyjnym a wykonaniem 
amputacji leczonej wcześniej kończyny. R= 0,99; 
R2= 0,99; popraw. R2= 0,99; F(31,1)=78292; p< 


















173.1 -75.1 0.01 
MCH (pg) 
MCH (pg) 









0.18 0.002 41.0 0.6 68.8 0.01 
MCV (fl) 
MCV (fl) 




0.32 0.01 13.6 0.3 41.7 0.02 
INR 
INR 

















0.67 0.004 404.3 2.3 173.4 0.004 













0.01 0.008 6.5 4.2 1.5 0.37 





0.84 0.01 202.1 3.4 59.1 0.01 
Hemoglobin (g/dl) 
HB (g/dl) 
5.42 0.05 785.4 6.9 112.7 0.006 
Hematocrit (%) 
HT (%) 










Rutherford (class 4-6) 
Rutherford (klasa 4-6) 
-0.21 0.01 -91.2 2.1 -44.3 0.01 
CABG history 
CABG w wywiadzie 
-0.24 0.01 -163.3 3.9 -40.9 0.02 
PCI history 
PTCA w wywiadzie 




Diabetes mellitus  
Cukrzyca  
0.04 0.01 22.8 3.2 7.2 0.09 
Glucose (mg/dl) 
Glukoza we krwi 
(mg/dl) 
0.14 0.01 0.6 0.04 14.1 0.04 








-0.30 0.01 -162.3 3.0 -54.2 0.012 
Severity of changes at 
femoropopliteal level 
according to TASC II 




-0.1 0.01 -0.6 0.05 -12.5 0.05 
aPTT (s) 
aPTT (s) 
0.31 0.003 15.3 0.1 123.9 0.005 
Severity of changes at 
aortoiliac level 
according to TASC II 




0.44 0.002 2.5 0.01 178.4 0.002 
Platelet count (G/l) 
Liczba płytek krwi 
(G/l) 
0.23 0.01 0.5 0.02 32.4 0.02 
Statin therapy 0.19 0.003 207.6 3.1 68.1 0.01 




Severity of changes in 
previously treated 
segment according to 
TASC-II 
Nasilenie z zmian w 
leczonym wcześniej 
odcinku wg TASC  
0.69 0.02 94.6 2.3 41.8 0.02 
Stroke history 
UDAR w wywiadzie 
0.39 0.01 288.0 9.6 29.9 0.02 
Cholesterol LDL 
(mg/dl) 
Stężenie LDL (mg/dl) 
0.11 0.003 1.0 0.03 35.2 0.02 
Gender (male / 
female) 
Płeć (męska/ żeńska) 




0.01 0.005 4.8 1.6 2.9 0.21 
Abbreviations: MCH = mean corpuscular hemoglobin; MCV = 
mean corpuscular volume; INR = international normalized ratio; 
MPV = mean platelet volume; CABG = coronary artery bypass graft; 
PCI = percutaneous coronary intervention; CAD = coronary artery 





The study retrospectively analyzed risk factors for 
the amputation of 39 lower limbs performed in our 
clinic between 2012 and 2014. The variables 
determining the duration of the period between the first 
revascularization and secondary amputation in 
multifactorial analysis were also defined. The only 
significant risk factors for primary amputation were the 
absence of aspirin, clopidogrel and statin 
pharmacotherapy (Table 1), which was most likely due 
to a delay in diagnosing the chronic lower limb 
ischemia. Older age, CHF and CKD were associated 
with an increased probability of a major amputation at 
the thigh level (Table 2). Multivariate analysis showed 
that the length of time between the first 
revascularization procedure and limb amputation was 
determined by a number of factors (Table 3), such as: 
the severity of atherosclerosis in the arteries of the 
aortoiliac segment (TransAtlantic Intersociety 
Consensus II; TASC II) [3], the presence of risk factors 
for atherosclerosis (e.g. tobacco smoking), use of 
adequate pharmacotherapy (e.g. statins), cardiovascular 
comorbidity (e.g. atrial fibrillation or a history of 
stroke), as well as some abnormalities in hematological 
or biochemistry laboratory values (e.g. leukocyte 
count, platelet count, INR, activated partial 
thromboplastin time [aPTT]). These data corroborate 
the results of other publications [3]. However, it is 
puzzling that diabetes mellitus, which is recognized as 
one of the strongest risk factors for CLI and lower limb 
amputation [3], showed similar prevalence in patients 
with primary and secondary amputation (Table 1), as 
well as with amputation at the thigh and forefoot level 
(Table 2). This factor was also not included in the 
multiple regression model determining the length of 
time between the first revascularization and amputation 
(Table 3). These discrepancies were most likely to 
have resulted from the relatively small number of 
patients studied or from better diabetes care than ten 
years ago, when TASC II was prepared. On the other 
hand, a smoking habit, atrial fibrillation and age 
achieved statistical significance (Table 3). Another 
interesting and seemingly paradoxical finding was the 
positive correlation of LDL cholesterol level with the 
length of time between the first procedure and 
amputation (Table 3), indicating that higher LDL 
cholesterol level delayed the amputation and 
suggesting a leg-saving effect, similar to the lipid-
lowering function of statins (Table 3), and in contrast 
with widely accepted data showing on harmful effect 
of dyslipidemia [4-9] and the favorable effect of statin 
therapy [7, 10-12]. The only reasonable explanation of 
these discrepancies is a lipid-lowering effect of 
cachexia reported previously in patients with CLI [13]. 
In this context, a low LDL cholesterol level did not 
reflect the level of the risk factor of atherosclerosis, but 
only the degree of metabolic devastation of the 
organism. Similar conclusions were drawn by Owens 
et al. [13] among patients who were qualified for a 
femoropopliteal bypass. In that cohort, those with CLI  
who died during the observation period had a 
significantly lower LDL cholesterol concentration than 
patients with intermittent claudication who had 
survived the observation period. Owens et al. [13] 
indicated a positive correlation between blood 
cholesterol and albumin concentration, which, in their 
opinion, confirmed an association between limb 
amputation and a patient’s poor nutritional status. In 
this regard, our observation does not contradict the 
recognition of dyslipidemia as a factor of risk and 
progression [3-7]. In contrast, the positive effect of 
statin intake on delaying amputation (Table 3) and the 
lower prevalence of statin  therapy in the group of 
patients with a primary amputation (Table 1) suggest 
that the effect of pleiotropic statins is predominant in 
relation to the lipid-lowering effect in the prevention of 
amputation. Many data confirm the positive impact of 
statins on the course of lower limb ischemia [10-12, 
14-16], claudication distance [10, 11, 17], and the 
prevalence of cardiovascular events in patients with 
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CLI [15, 18, 19], although statin therapy has no 
influence on the risk of amputation [16].  
The positive correlation of the severity of changes 
in the aortoiliac segment according to TASC II and its 
update [3, 20] and the length of time between the first 
procedure and amputation (Table 3) also seems to be 
paradoxical. However, this should come as no surprise 
when taking into consideration the fact that in 
medicine the sickest receive the greatest benefit. For 
example, patients who undergo coronary 
revascularization for cardiogenic shock or the efficacy 
of thrombolysis for stroke. Furthermore, the greater 
severity of the atherosclerotic changes in the proximal 
arteries of the lower limb, the stronger the release of 
angiogenesis stimulating factors [21], which can 
improve the peripheral perfusion. 
There are some practical implications resulting 
from this study. Firstly, it is worth considering a 
screening program for lower limb ischemia, at least in 
certain groups of patients, to prevent delays both in the 
diagnosis of PAD and in introducing treatment with 
aspirin and statins, which improve patients’ symptoms, 
improve the outcome of leg revascularization and can 
prolong the time between a procedure and amputation 
(Tables 1 and 3). Secondly, in our study, only 15% of 
patients underwent primary leg amputation, which is a 
better result than previously reported 50% of primary 
amputations [3]. Thirdly, we found a positive 
correlation between the number of revascularizations 
and delayed amputation time (Table 3). Therefore, 
every patient with CLI should, if possible, undergo 
lower limb revascularization and, in the case of the 
recurrence of leg ischemia (e.g. due to stent 
insufficiency), it is always worth performing another 
procedure with stent implantation with the required 
number of stents (Table 3). As a result, controversies 
concerning extensive stenting of lower extremity 
arteries and a recommendation to avoid “full metal 
jacket” stenting seem to appeal more to patients with 
intermittent claudication than with CLI [21-23]. 
Fourthly, statin therapy for patients with PAD should 
be recommended not only for atherosclerosis of lower 
limb arteries, but also for cardiovascular comorbidities, 
such as coronary artery diseases and previous strokes 
(Tables 1 and 2). The treatment should aim to achieve 
the target level of blood lipids recommended by the 
European Society of Cardiology [4-7]. 
The authors of this study are aware of its 
limitations. The low number of amputated limbs in the 
analysis and the disproportionate number of primary 
and secondary amputations may affect the strength and 
reliability of the reasoning. Despite these limitations, 
many of the comparisons made in the analyzed groups 




1. Among patients who underwent lower limb 
amputation due to CLI, 15% were admitted to 
hospital in a condition that did not allow the 
performance of a revascularization procedure, 
which suggests the need for an improvement in 
patient education so that they can be referred earlier 
to vascular centers. A substantial percent (54%) of 
the patients needed just a small amputation at the 
level of forefoot and did not need any further 
radical surgeries during the two years of 
observation, most probably due to the effect of 
previous revascularization procedures. 
2. Patients who underwent a thigh-level amputation 
stayed in hospital  twice as long compared with 
those who had less radical surgeries. The main 
factors determining the time between a 
revascularization procedure and amputation, as well 
as its level, were as follows: the number of 
procedures and stent implantations in the patient’s 
history, the coexistence of CHF and CKD, tobacco 
smoking, inadequate pharmacotherapy, and the 
severity of changes revealed by angiography. 
Paradoxically, there was no influence of diabetes 
mellitus and dyslipidemia on these outcomes. 
3. Amputations were delayed by successive 
revascularization procedures (at least two 
procedures in the majority of patients) and stenting 
the vessels. Therefore, it is worth to perform a 
revascularization procedure in every possible case, 
as well as it is necessary to inform patients to 
contact a vascular specialist without delay when 
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